Phase 2 N=69 A Study of Clofarabine in Older Patients With Acute Myeloid Leukemia (AML) for Whom Chemotherapy Is Not Suitable
Acute Myeloid Leukemia
Primary: Overall Response Rate (ORR) — 48 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=93 TAP Block in DIEP or Free MS-TRAM Donor Site: A RCT
Transversus Abdominis Plane (TAP) Block Catheter · DIEP or Free MS-TRAM Breast Reconstruction · Local Pain Management
Primary: Mean Total Opioid Consumption — 30.0; 20.7 mg — p=0.02
Phase 2 N=51 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
Gastrin-Producing Neuroendocrine Tumor · Lung Carcinoid Tumor · Metastatic Digestive System Neuroendocrine Tumor G1
Primary: Objective Response Rate (Complete and Partial Response) for Each Cohort Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) — 0; 6; 14; 21 participants
Phase 2 N=42 Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer
Prostate Cancer
Primary: Change in the Number of Infiltrating CD3+ T Cells Within the Prostate Tissue Between the Biopsy and the Post-RP Tissue Specimens in Each Subject — 2.33; 2.03; 1.98; 6.39…
Phase 4 N=68 Effects of N-acetylcysteine on Low T3 Syndrome
Acute Myocardial Infarction · Euthyroid Sick Syndrome · Ischemic Heart Disease
Primary: Serum T3 Levels at 48 Hours — 93.5; 96.5 ng/dL
Phase 1 N=33 Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Phase II: Overall Response Rate — 21.8 Percentage of Participants
N/A N=66 In Vivo nCLE Study in the Pancreas With Endosonography of Cystic Tumors
Pancreatic Cysts
Primary: Sensitivity — 59 percentage of participants
Phase 3 N=74 Open-label, Extension Study of Aripiprazole Intramuscular Depot (OPC-14597, Lu AF41155) in Patients With Schizophrenia
Schizophrenia
Primary: Percentage of Participants Reporting Treatment Emergent Adverse Events (TEAEs), Severe TEAEs, Discontinued Investigational Medicinal Product (IMP) Due to AEs, Serious…
N/A N=48 Efficacy Study of Dextromethorphan to Treat Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Good European League Against Rheumatism (EULAR) Therapeutic Response Rate — 6; 4 participants
Phase 2 N=53 A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer
Solid Tumors and Advanced Endometrial Cancer · Endometrial Cancer · Second-line Treatment
Primary: Progression Free Survival (PFS) Rate — 31.8; 29.0 Percentage of participants
Phase 3 N=405 3 Month Safety Study of Dymista Nasal Spray and Fluticasone Propionate in Children 4-11 Years of Age With Allergic Rhinitis
Allergic Rhinitis
Primary: Adverse Events Report — 124; 37 event
Phase 2 N=46 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma
Childhood Alveolar Soft Part Sarcoma · Childhood Angiosarcoma · Childhood Epithelioid Sarcoma
Primary: Objective Response Rate (PR or CR) by Response Evaluation Criteria in Solid Tumors (RECIST). — 10; 11; 11; 11 participants
Phase 4 N=54 Effects of Nicorandil on Angina Symptoms in Patients With Coronary Slow Flow
Slow Coronary Flow · Normal, or Near Normal Coronary Angiography · Stable Angina
Primary: Angina Episode Frequnecy — 2.28; 1.68 episodes per week
N/A N=128 NEP-TUNE: Neuropathic Pain - Treatment With Pregabalin Under Real-life Conditions in Denmark
Peripheral Neuropathic Pain
Primary: Change From Baseline In Average Pain Level At Month 3 Telephonic Interview — 6.7; -2.2 Units on a scale — p=<0.001
N/A N=242 Basel Discharge Communication Project
Emergency Service, Hospital · Information Structuring · Physician-Patient Relations
Primary: Number of Items Recalled From the Communication in the Video — 8.12; 5.71; 9.95; 8.76 number of items recalled